![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Versus Dolutegravir (DTG)-Based 3-Drug Regimens in Adults With HIV Who Have Suboptimal Antiretroviral Adherence
|
|
|
ID Week 2023 Oct 11
risten Andreatta,1 Paul E. Sax,2 David Wohl,3 Michelle L. D'Antoni,1 Hailin Huang,1 Jason Hindman,1 Christian Callebaut,1 Hal Martin1
1Gilead Sciences, Inc., Foster City, CA, U.S.A.; 2Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, U.S.A.; 3Division of Infectious Diseases, University of North Carolina, Chapel Hill, NC, U.S.A
![1012231](../images/101023/101023-8/1012231.gif)
![1012232](../images/101023/101023-8/1012232.gif)
![1012233](../images/101023/101023-8/1012233.gif)
![1012234](../images/101023/101023-8/1012234.gif)
![1012235](../images/101023/101023-8/1012235.gif)
![1012236](../images/101023/101023-8/1012236.gif)
![1012237](../images/101023/101023-8/1012237.gif)
![1012238](../images/101023/101023-8/1012238.gif)
![1012239](../images/101023/101023-8/1012239.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|